BAG Dres. med. Quist PartG

Mainz 10 trials 5 recruiting

10 Registered trials

5 Currently recruiting

Organisation

BAG Dres. med. Quist PartG

Location

Mainz, Germany

Identifier

ORL-000001103

Address

Haifa-Allee 20, 55128, Germany

Departments

BAG Dres. med. Quist PartG
Dermatologie
Dermatologie Quist - BAG Dres. Quist PartG
N/A
NA

Clinical trials at this site (10)

Search interface

A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending

2024-513740-28-00 Respiratory Syncytial Virus and Human Metapneumovirus 5
Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting

2025-521293-34-00 Moderate-to-severe hidradenitis suppurativa 4 2025-12-09
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder… Recruiting

2023-506296-97-00 Moderate to Severe Plaque Psoriasis 5 2025-10-28
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult… Recruiting

2023-505218-68-00 Moderate-Severe Atopic Dermatitis 4 2025-06-12
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting

2023-503661-28-00 Hidradenitis Suppurativa 5 2023-10-26
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended

2022-502700-78-00 Alopecia areata (AA) 5 2023-09-01
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15
Evaluating the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Ended

2023-508820-37-00 Cytomegalovirus Infection (CMV) 5 2022-02-03